Literature DB >> 28126652

A de novo mutation in the X-linked PAK3 gene is the underlying cause of intellectual disability and macrocephaly in monozygotic twins.

Jozef Hertecant1, Makanko Komara2, Aslam Nagi3, Olfat Al-Zaabi4, Waseem Fathallah5, Hong Cui6, Yaping Yang6, Christine M Eng6, Mohammad Al Sorkhy7, Mohammad A Ghattas7, Lihadh Al-Gazali8, Bassam R Ali9.   

Abstract

Pathogenic variants in theP21 protein (Cdc42/Rac)-activated kinase 3gene (PAK3) lead to a rare non syndromic X-linked intellectual disability. The protein encoded by this gene forms an activated complex with GTP-bound RAS-like (P21), CDC2 and RAC1 proteins which then mediates a variety of cellular processes. So far, mutations in PAK3 gene have been reported in few families affected with intellectual disability associated with neurological manifestations such as speech defect, behavioral problem, brain structural abnormalities, microcephaly and cerebral palsy. In this study whole exome sequencing revealed a de novo likely pathogenic variant in PAK3 gene in monozygotic twins presented with intellectual disability, speech delay, behavioral problems and macrocephaly. Macrocephaly was noticed in our patients from birth at 35 weeks of gestation. This aspect of the phenotype has not been previously reported in other documented cases with pathogenic mutations in PAK3 gene. Our findings extend the phenotype of this disorder to include macrocephaly and offers further clues to the importance of the serine/threonine-protein kinase 3 (PAK3) protein in brain development and function.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Intellectual disability; Macrocephaly; PAK3; X-linked; de novo mutation

Mesh:

Substances:

Year:  2017        PMID: 28126652     DOI: 10.1016/j.ejmg.2017.01.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

1.  Activating Mutations in PAK1, Encoding p21-Activated Kinase 1, Cause a Neurodevelopmental Disorder.

Authors:  Frederike L Harms; Katja Kloth; Annette Bley; Jonas Denecke; René Santer; Davor Lessel; Maja Hempel; Kerstin Kutsche
Journal:  Am J Hum Genet       Date:  2018-10-04       Impact factor: 11.025

Review 2.  NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment.

Authors:  Ana Fernandez-Marmiesse; Sofia Gouveia; Maria L Couce
Journal:  Curr Med Chem       Date:  2018-01-30       Impact factor: 4.530

3.  Counter-Balance Between Gli3 and miR-7 Is Required for Proper Morphogenesis and Size Control of the Mouse Brain.

Authors:  Longbin Zhang; Taufif Mubarak; Yase Chen; Trevor Lee; Andrew Pollock; Tao Sun
Journal:  Front Cell Neurosci       Date:  2018-08-17       Impact factor: 5.505

4.  Solution structures and biophysical analysis of full-length group A PAKs reveal they are monomeric and auto-inhibited in cis.

Authors:  Fiona J Sorrell; Lena Marie Kilian; Jonathan M Elkins
Journal:  Biochem J       Date:  2019-04-04       Impact factor: 3.857

Review 5.  A novel PAK3 pathogenic variant identified in two siblings from a Japanese family with X-linked intellectual disability: case report and review of the literature.

Authors:  Aritoshi Iida; Kyoko Takano; Eri Takeshita; Chihiro Abe-Hatano; Shinichi Hirabayashi; Yuji Inaba; Shunichi Kosugi; Yoichiro Kamatani; Yukihide Momozawa; Michiaki Kubo; Eiji Nakagawa; Ken Inoue; Yu-Ichi Goto
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-12-13

6.  Novel PAK3 gene missense variant associated with two Chinese siblings with intellectual disability: a case report.

Authors:  Yanyan Qian; Bingbing Wu; Yulan Lu; Wenhao Zhou; Sujuan Wang; Huijun Wang
Journal:  BMC Med Genet       Date:  2020-02-12       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.